Yale Drug use, Addiction and HIV Research Scholars (DAHRS)

7.项目摘要/摘要 耶鲁大学-药物使用、成瘾和艾滋病毒研究学者计划(DAHRS)始于2013年，目的是 培养一批来自多个医学专业的不同的年轻教员，以满足发展 一批训练有素的临床医生学者，负责与药物有关的生物医学、行为和临床研究 在普通医疗环境中使用、上瘾和艾滋病毒预防和治疗。吸食药物的病人 疾病通常在普通医疗机构接受医疗护理，如初级保健诊所和急诊 部门；艾滋病毒、青少年和妇女健康及其他专科诊所；呈现复杂的阵列 物质的急性后果和并发症(例如，中毒、过量用药、戒断和创伤) 使用和慢性疾病，如疼痛、艾滋病、肝炎、肺病和心脏病。病人是 越来越多地向这些环境介绍成瘾本身的预防和治疗。耶鲁-达赫斯 该计划提供全面的三年博士后，跨学科指导的职业发展 包含强大的教学研究课程的计划，最终获得健康科学硕士学位 与成瘾医学相关的学位、指导研究和培训：[目标1]培养临床医生 具有成为独立调查人员的知识、技能和能力的科学家，产生 对改善有吸毒、成瘾和吸毒风险的患者的健康具有重大影响的实用价值 [目标2]通过为学者提供领导技能和创造个性化的方式培养未来的领导者 确保成功领导多学科研究团队研究药物使用、成瘾和 艾滋病毒，以及将研究成果落实和纳入普通医疗环境；[目标3] 增强药物使用、成瘾和艾滋病毒研究人员的多样性。支持妇女和妇女的事业 代表不足的少数族裔教职员工增加了调查人员和研究主题的多样性，拓宽了 在设定研究优先顺序、增加临床试验参与度和扩大知识方面的观点。至 到目前为止，我们的计划已经成功地利用了现有培训和临床的协同效应 耶鲁大学的课程和我们的社区合作伙伴，以及我们经验丰富、多样化的 跨学科核心教师、导师和咨询委员会。我们招收了五名学者(四名女性) 来自内科、儿科、急诊、妇产科、肺科等领域 医药。这三名毕业生都接受了学术研究的职位。其中一人获得了独立的NIDA R01资助，是美国国立卫生研究院资助的两项赠款的联合调查员；其中一项从两项PI试点资金中获得 NIH机构赠款，正在等待R21 NIH审查；第三个是NIDA和CDC的联合调查员 目前正在等待对两笔赠款的审查。所有这些都发表在影响力很大的期刊和教科书上，并 他们的临床专业领域的新兴领军者。第一次续期支持四位学者，受益于 我们已经进行了迭代更改，以改进程序，增加了下一代调查人员。

7. Project Summary/Abstract The Yale-Drug use, Addiction and HIV Research Scholar program (DAHRS) began in 2013 with the aim of training a group of diverse young faculty from multiple medical specialties to meet the critical need to develop a pool of highly trained clinician scholars to conduct biomedical, behavioral and clinical research related to drug use, addiction, and HIV prevention and treatment in general medical settings. Patients with substance use disorders often receive medical care in general medical settings such as primary care clinics and emergency departments; HIV, adolescent and women's health and other specialty clinics; presenting with a complex array of acute consequences and complications (e.g. intoxication, overdose, withdrawal, and trauma) of substance use and chronic conditions such as pain, HIV disease, hepatitis, pulmonary and cardiac disease. Patients are increasingly presenting to these settings for the prevention and treatment of addiction itself. The Yale-DAHRS program provides a comprehensive three year post-doctorate, interdisciplinary Mentored Career Development Program that incorporates a robust didactic research curriculum leading to a Masters in Health Science degree, mentored research and training in topics related to Addiction Medicine to: [Aim 1] Develop clinician scientists with the knowledge, skills, and ability to become independent investigators, generating findings of practical value with significant impact to improve health in patients with and at risk for drug use, addiction, and HIV; [Aim 2] Develop future leaders by providing Scholars with leadership skills and creating individualized programs to ensure success in leading multidisciplinary research teams in studying drug use, addiction and HIV, and implementation and integration of research findings into general medical settings; and [Aim 3] Enhance the diversity of drug use, addiction, and HIV researchers. Supporting the careers of women and under-represented minority faculty enhances the diversity of investigators and research topics, broadens perspectives in setting research priorities, increases clinical trial participation, and expands knowledge. To date, our program has demonstrated success capitalizing on the synergies of established training and clinical programs at Yale and our community partners, and the experiences offered by our seasoned, diverse group of interdisciplinary core faculty, mentors and advisory committee. We have enrolled five Scholars (four women) from the fields of internal medicine, pediatrics, emergency medicine, obstetrics and gynecology and pulmonary medicine. All three graduates accepted academic research positions. One has received independent NIDA R01 funding and is co-investigator on two NIH funded grants; one received PI pilot funding from two institutional NIH grants and is awaiting an R21 NIH review; the third is a co-investigator on NIDA and CDC grants and is awaiting review on two grants. All have published in high impact journals and textbooks and are emerging leaders in their clinical specialties. This first time renewal supports four Scholars, benefiting from the iterative changes we have made to improve the program, adding to the next generation of investigators.